IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

Background: Non-canonical mutations of the isocitrate dehydrogenase (IDH) genes have been described in about 20–25% and 5–12% of patients with WHO grade II and III gliomas, respectively. To date, the prognostic value of these rare mutations is still a topic of debate. Methods: We selected patients w...

Full description

Bibliographic Details
Main Authors: Enrico Franceschi, Dario De Biase, Vincenzo Di Nunno, Annalisa Pession, Alicia Tosoni, Lidia Gatto, Giovanni Tallini, Michela Visani, Raffaele Lodi, Stefania Bartolini, Alba Ariela Brandes
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Diagnostics
Subjects:
glioma
WHO grade II glioma
WHO grade III glioma
IDH1
prognostic factor
Online Access:https://www.mdpi.com/2075-4418/11/2/342

Internet

https://www.mdpi.com/2075-4418/11/2/342

Similar Items